Bringing the Oncology Community Together
Expanded Mutation Analysis Fails to Resolve Targeted Therapy Quandary in Metastatic CRC
All patients with metastatic colorectal cancer should undergo RAS mutation testing to ensure optimal patient selection for EGFR inhibitor therapy.
Read More >>
Pembrolizumab Shows Promise in Advanced Gastric Cancer
Dovitinib Meets Primary Endpoint in Phase II Trial of Advanced GIST
Potentially Curative Surgery Achievable With Chemo/SABR Combination for Advanced Pancreatic Cancer
Ramucirumab Improves Survival in mCRC
Immunotherapy Combined With Chemotherapy for Pancreatic Cancer: A Game Changer?
Four Distinct Subtypes of Gastric Cancer Found
View More >>
- A Network of Your Peers
View more >>
Dr. Saab on a Phase II Study of the Oncolytic Virus Reolysin for Pancreatic Cancer
TAS-102 in Refractory mCRC
The Pivotal Role of Cooperative Group Trials
Most Popular Right Now
Tweets by @OncLive
New Metastatic Colorectal Cancer iPub
Insight from Fadi Braiteh, MD, and Robin Wachsman, RN, BS, OCN, CCRN, CBCN, on regorafenib in mCRC.
Treatment Considerations in Refractory CRC
Moderated by John L. Marshall, MD, this panel discussion includes expert perspectives from Johanna Bendell, MD, Marwan Fakih, MD, Heinz-Josef Lenz, MD, and Alan P. Venook, MD.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.